Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects

Inclusion Criteria

• •Early PD Subjects
• •The participant is 30 years or older.
• •Written informed consent is obtained.
• •Participants have a diagnosis of PD (based on UK Brain Bank Criteria) within the past 2 years.
• •Modified Hoehn and Yahr stages 1-2.
• •No evidence of dyskinesia by history or clinical examination
• •For females, non-child bearing potential or a negative urine or blood pregnancy test on day of \[18F\]-MK-9470 injection.
• •Advanced PD subjects
• •The participant is 30 years or older.
• •Written informed consent is obtained.
• •Participants have a diagnosis of PD (based on UK Brain Bank Criteria) of at least 5 years duration.
• •Modified Hoehn and Yahr stages 1-4.
• •No evidence of dyskinesia by history or clinical examination
• •For females, non-child bearing potential or a negative urine or blood pregnancy test on day of \[18F\]-MK-9470 injection.
• •Subjects who have a clinical diagnosis of advanced PD with dyskinesia will be recruited for this study.
• •ePD subjects
• •The participant is 30 years or older.
• •Written informed consent is obtained.
• •Participants have a diagnosis of PD (based on UK Brain Bank Criteria) of at least 5 years.
• •Modified Hoehn and Yahr stages 1-4.
• •Evidence of dyskinesia either by history or clinical examination
• •For females, non-child bearing potential or a negative urine or blood pregnancy test on day of \[18F\]-MK-9470 injection.
• •PD (all stages- e-PD, aPD, aPD-dys)Subject Selection. Subjects who have a clinical diagnosis of ePD, aPD, aPD-dys will be recruited for this study.
• •All PD subjects
• •The participant is 18 years or older.
• •Written informed consent is obtained.
• •Negative history of neurological or psychiatric illness based on evaluation by a research physician.
• •For females, non-child bearing potential a negative urine or blood pregnancy test on day of \[18F\]-MK9470 injection.